We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes.
- Authors
Yang, Kun; Wang, Haining; Wei, Rui; Xiao, Wenhua; Tian, Qing; Wang, Chen; Yang, Jin; Hong, Tianpei
- Abstract
Aims: To investigate the association between fibroblast growth factor 21 (FGF21) levels and glycemic response to exenatide in patients with type 2 diabetes. Methods: The exploratory analysis of a multi-center trial included 190 patients with type 2 diabetes inadequately controlled by monotherapy or combination therapy of metformin and insulin secretagogues. All participants received exenatide twice daily as an add-on therapy for 16 weeks. Serum FGF21 and other information at the baseline and end of follow-ups were obtained. Linear regression analysis was used to determine the correlations between baseline FGF21 levels and HbA1c reduction from baseline after the treatment. Results: After 16 weeks of treatment with exenatide, a decline in the HbA1c levels from baseline was associated with higher baseline FGF21 levels among all participants (r = 0.193, P = 0.008) and in subgroup of the participants receiving background metformin monotherapy (r = 0.231, P = 0.034). Compared with patients in the lowest FGF21 quartile, patients in the highest FGF21 quartile showed a significantly weakened decline in HbA1c levels from baseline among all participants (β = − 0.16 [95% Cl − 0.31 to − 0.01], P < 0.05) and in subgroup of the participants receiving background metformin monotherapy (β = − 0.23 [95% Cl − 0.43 to − 0.03], P < 0.05), after adjusting for the confounding factors, including age, sex, and baseline HbA1c levels. Conclusions: The high baseline FGF21 levels are associated with poor glycemic responses to exenatide in patients with type 2 diabetes. Therefore, FGF21 could be used as a biomarker for predicting the efficacy of exenatide treatment. Trial registration: ChiCTR-IPR-15006558, date registered May 27, 2015.
- Subjects
METFORMIN; GLYCEMIC index; TYPE 2 diabetes; FIBROBLAST growth factors; EXENATIDE; GLUCAGON-like peptide-1 receptor; GHRELIN receptors
- Publication
Acta Diabetologica, 2021, Vol 58, Issue 5, p595
- ISSN
0940-5429
- Publication type
Article
- DOI
10.1007/s00592-020-01660-z